Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritic Psoriasis Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
placebo, ustekinumab 45 mg, ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 30 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jun 10, 2026, 4:50 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

NCT06454188
View directory record Official record
Conditions
Psoriatic Arthritis, Spondyloarthritis, Axial
Interventions
Upadacitinib 15 MG [Rinvoq], Placebo
Drug
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis

NCT04269993
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Cannabis: placebo and medium THC/medium CBD
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

NCT01882439
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jun 10, 2026, 4:50 AM EDT
Completed No phase listed Observational

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

NCT05421442
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38,396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jun 10, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo, Risankizumab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
44
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

NCT02584855
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
38
States / cities
Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

NCT01877668
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jun 10, 2026, 4:50 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

NCT03626038
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Interventions
A.L.P.S. Proximal Humerus Plating System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

NCT01198509
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions
doxycycline, vancomycin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis

NCT03409211
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
PEVCO, Dietary Supplement Capsules without Coconut Oil
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Early Phase 1 Interventional

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

NCT00643526
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions
Pre-filled Auto-injector Containing Placebo
Device
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jun 10, 2026, 4:50 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

NCT00023205
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Polyarthritis
Interventions
11th grade reading level arthritis materials, Interactive in-person arthritis education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Results available

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

NCT02019602
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Jun 10, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

NCT03347110
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jun 10, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

NCT05511519
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ATI-450, Placebo Oral Tablet
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Miami Lakes, Florida • Tampa, Florida • Freehold, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 10, 2026, 4:50 AM EDT
Completed No phase listed Observational Results available

Psoriatic Arthritis Research Collaborative: Biologic Sub-Study

NCT03378336
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
171 participants
Timeline
2017 – 2023
U.S. locations
4
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jun 10, 2026, 4:50 AM EDT